Gilead Sciences (GILD) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $58.5 billion.
- Gilead Sciences' Liabilities and Shareholders Equity rose 735.08% to $58.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $229.7 billion, marking a year-over-year increase of 139.59%. This contributed to the annual value of $59.0 billion for FY2024, which is 503.82% down from last year.
- Gilead Sciences' Liabilities and Shareholders Equity amounted to $58.5 billion in Q3 2025, which was up 735.08% from $55.7 billion recorded in Q2 2025.
- Over the past 5 years, Gilead Sciences' Liabilities and Shareholders Equity peaked at $68.0 billion during Q2 2021, and registered a low of $53.6 billion during Q2 2024.
- Over the past 5 years, Gilead Sciences' median Liabilities and Shareholders Equity value was $62.3 billion (recorded in 2023), while the average stood at $61.3 billion.
- Per our database at Business Quant, Gilead Sciences' Liabilities and Shareholders Equity skyrocketed by 2154.32% in 2021 and then plummeted by 1404.94% in 2024.
- Quarter analysis of 5 years shows Gilead Sciences' Liabilities and Shareholders Equity stood at $68.0 billion in 2021, then fell by 7.04% to $63.2 billion in 2022, then dropped by 1.66% to $62.1 billion in 2023, then fell by 5.04% to $59.0 billion in 2024, then fell by 0.78% to $58.5 billion in 2025.
- Its Liabilities and Shareholders Equity was $58.5 billion in Q3 2025, compared to $55.7 billion in Q2 2025 and $56.4 billion in Q1 2025.